SD vs. ED Natalizumab study: a single CSF cell study

Brief description of study

The overall purpose of the study is to compare differences in cerebrospinal fluid (CSF) among relapse-remitting MS patients on different dosing intervals of Natalizumab, as well as to capture baseline characteristics among relapse-remitting MS patients on these different dosing intervals, including but not limited to, disease duration and course, treatment history, MRI lesion burden, activity level, and various study assessment scores. The study will refer the participant to Columbia University Medical Center (CUMC) for participation in a study and to provide CUMC with information from your medical record needed for the study.

Clinical Study Identifier: s18-00748
Principal Investigator: Lana Zhovtis Ryerson
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.